Urothelial Carcinoma (transitional carcinoma)

Urothelial carcinoma, also known as transitional cell carcinoma, is a type of cancer that primarily affects the urinary system, including the bladder, ureters, and renal pelvis. This malignancy arises from the urothelial cells lining the inner surface of these organs. As a prevalent form of bladder cancer, understanding urothelial carcinoma's diagnosis, pathology, causes, staging, treatment, risk factors, and symptoms is crucial for effective management and patient care.

Understanding Urothelial Carcinoma

Urothelial carcinoma accounts for about 90% of all bladder cancers. It is characterized by the abnormal proliferation of urothelial cells, which can lead to various degrees of malignancy. While it often manifests in the bladder, it can also occur in the ureters and renal pelvis, albeit less frequently.

Secure your health with a second opinion. Make informed decisions and book your appointment today!

Get A Second Opinion

Causes and Risk Factors

The aetiology of urothelial carcinoma involves a combination of genetic and environmental factors. Understanding these can aid in prevention and early detection.

Urothelial Carcinoma Causes

Tobacco Smoking: Smoking is the most significant risk factor for urothelial carcinoma. Carcinogens in tobacco smoke are excreted in urine, directly affecting the urothelial cells.
Chemical Exposure: Occupational exposure to chemicals, such as those used in the dye, rubber, and leather industries, can increase cancer risk.
Chronic Irritation: Long-term irritation of the bladder lining, due to factors like urinary infections or bladder stones, may contribute to carcinogenesis.

Urothelial Carcinoma Risk Factors

Age and Gender: The risk of urothelial carcinoma increases with age, and it is more common in males than females.
Family History: A family history of bladder cancer can elevate risk, suggesting a genetic predisposition.
Previous Cancer Treatments: Patients who have undergone radiation therapy or certain chemotherapy treatments have a higher risk of developing urothelial carcinoma.

Urothelial Carcinoma Symptoms

Early symptoms of urothelial carcinoma may be subtle and easily overlooked. Common symptoms include:

Hematuria: Blood in the urine is the most common symptom, often appearing suddenly and without pain.
Frequent Urination: Increased urgency and frequency of urination can occur, sometimes accompanied by pain or discomfort.
Back or Abdominal Pain: Pain may be indicative of advanced disease or when the cancer has spread to other areas.

Urothelial Carcinoma Diagnosis

Diagnosis of urothelial carcinoma typically begins with a thorough clinical evaluation, including a review of the patient's medical history and physical examination. Diagnostic procedures may include urine cytology, cystoscopy, and imaging studies such as CT urograms or MRI.

Urine Cytology: This test involves examining urine samples for cancerous cells. While not definitive, it can suggest the presence of a malignancy.
Cystoscopy: A cystoscope is inserted through the urethra to visualize the bladder's interior. This procedure allows for direct observation and biopsy of suspicious lesions.
Imaging Studies: CT scans or MRIs provide detailed images of the urinary tract, helping identify tumours and their extent.

Urothelial Carcinoma Pathology Outlines

Pathological examination is integral to diagnosing and staging urothelial carcinoma. The pathology outlines include assessing tumour grade, depth of invasion, and presence of any variant histology.

Tumour Grade: Urothelial carcinoma is classified into low-grade and high-grade tumours. Low-grade tumours are less aggressive, while high-grade tumours are more likely to invade surrounding tissues and metastasize.
Depth of Invasion: Pathologists assess how deeply the tumor has invaded the bladder wall or other affected areas. The depth of invasion is a key factor in staging and treatment planning.
Variant Histology: Certain histological variants, such as micropapillary, nested, or plasmacytoid, can influence prognosis and treatment decisions.

Urothelial Carcinoma Staging

Staging urothelial carcinoma involves determining the extent of the disease, which is crucial for prognosis and treatment planning.

Stage 0: Cancer cells are found on the surface of the bladder lining (carcinoma in situ).
Stage I: Cancer has invaded the connective tissue beneath the lining of the bladder.
Stage II: Cancer has spread to the muscle layer of the bladder wall.
Stage III: Cancer has extended through the bladder wall to surrounding tissues.
Stage IV: Cancer has metastasized to distant organs or lymph nodes.

Ready to take control of your health journey? Book your appointment now and start your path towards wellness today!

Book an Appointment

Treatment of Urothelial Carcinoma

Treatment strategies for urothelial carcinoma depend on the stage and grade of the tumour, as well as the patient's overall health.

Surgical Interventions

Transurethral Resection (TURBT): For non-muscle-invasive tumours, TURBT is a common procedure to remove cancerous tissue.
Radical Cystectomy: For muscle-invasive or high-risk non-muscle-invasive cancers, radical cystectomy (removal of the bladder) may be necessary.

Intravesical Therapy

BCG Therapy: Bacillus Calmette-Guérin (BCG) is a type of intravesical immunotherapy used to treat non-muscle-invasive bladder cancer.
Intravesical Chemotherapy: Chemotherapeutic agents can be directly instilled into the bladder to target cancer cells.

Systemic Therapy

Chemotherapy: Systemic chemotherapy may be used for advanced urothelial carcinoma, either alone or in combination with other treatments.
Immunotherapy: Immune checkpoint inhibitors, such as pembrolizumab, have shown promise in treating advanced cases.

Find Our Specialists